May We Use Non-Invasive Indices of Aortic Stiffness and Endothelial Glycocalyx as Biomarkers for Idiopathic Pulmonary Artery Hypertension Follow-Up?
Helen Triantafyllidi, Dionysia Birmpa, Dimitrios Benas, Ignatios Ikonomidis, Antonis Schoinas, Paraskevi Trivilou, Frantzeska Frantzeskaki and Stylianos E. Orfanos
MDPI (Multidisciplinary Digital Publishing Institute) 25 May 2021
Abstract
Idiopathic pulmonary arterial hypertension (IPAH) initial evaluation and follow-up, a rare and incurable disease if left untreated, is based on a multiparametric approach (functional status of the patient, biomarkers, hemodynamic parameters and imaging evaluation of right heart impairment). Arterial stiffness (AS) and endothelial glycocalyx are indices of systemic circulation. We present the 3-years follow-up of a female IPAH patient. We propose aortic stiffness and endothelial glycocalyx indices as non-invasive markers of either improvement or deterioration of IPAH disease.
Copyright © 2019-2024 NuLife Sciences, Inc. - A BioRegenx Company. All rights reserved.
The statements (appearing on this website) have not been evaluated by the Food and Drug Administration. NuLife products are not intended to diagnose, treat, cure, or prevent any disease. If you are pregnant, nursing, on medication, have a medical condition or beginning a weight control system, consult your physician before using NuLife products. *The testimonials presented apply only to the individuals depicted, cannot be guaranteed, and should not be considered typical.